Crossmark

Multiwavelength fluorescence imaging using a CEA-targeted fluorescent agent and indocyanine green to increase surgical precision in patients with colorectal liver metastases

Crossref DOI link: https://doi.org/10.1038/s41598-026-72110-z

Published Online: 2026-09-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Warmerdam, Mats I. https://orcid.org/0000-0002-4546-5966
Dijkhuis, Tom H.

Bijlstra, Okker D.

van Ravens, Thomas W.

van Dam, Martijn A.

Hartgrink, Henk H.

Burggraaf, J.

Crobach, A. Stijn L. P.

Cailler, F.

Vahrmeijer, Alexander L.

Mieog, J. Sven D.
License Information

Text and Data Mining valid from 2026-09-22

Accepted Manuscript valid from 2026-09-22
More Information

Article History

Received: 18 May 2026

Accepted: 15 September 2026

First Online: 22 September 2026

Declarations

Competing interests: F. Cailler is employed by SurgiMab, which owns the SGM-101 conjugate. F. Cailler is part of the SurgiMab founders and is stockholder. All other authors declare no competing interests.

Document is current

Any future updates will be listed below